Not medical advice. Talk to your provider before using any peptide. Full disclaimer
SS-31 (Elamipretide)
Beginner tier: 4 mg, daily · community consensus
Also known as: SS-31, MTP-131, Bendavia
FDA accelerated approval came through September 2025, making elamipretide one of only a handful of mitochondrial-targeted drugs to reach the market. SS-31 (brand name FORZINITY, also known as elamipretide, MTP-131, or Bendavia) is a four-amino-acid peptide that crosses into mitochondria and binds cardiolipin, a lipid that holds the electron transport chain together. The TAZPOWER trial earned approval based on knee extensor strength gains in Barth syndrome patients, though the randomized-phase primary endpoints were not met. Longevity researchers and biohackers now use SS-31 at community-derived doses between 2 and 10 mg daily for energy, recovery, and mitochondrial support.
What Is SS-31 (Elamipretide)?
Four amino acids. That is all SS-31 is. D-Arg-dimethylTyr-Lys-Phe-NH2, a tetrapeptide small enough to cross cell membranes without relying on mitochondrial membrane potential. It concentrates more than 1,000-fold inside mitochondria and locks onto cardiolipin, the phospholipid that anchors cytochrome c to the inner mitochondrial membrane.
SS-31 (elamipretide, CAS 736992-21-5, also called MTP-131 and Bendavia) earned FDA accelerated approval in September 2025 under the brand name FORZINITY (NDA 215244) for Barth syndrome in patients weighing at least 30 kg. The approval rested on open-label extension data from the TAZPOWER trial (n=12)[1], where knee extensor strength improved 42% from baseline at 168 weeks. The randomized-phase primary endpoints, 6-minute walk test and total fatigue score, were not met in the initial 12-week crossover.
Mechanistic evidence is strong. Cardiolipin oxidation collapses cristae, slows electron transfer between complexes III and IV, leaks electrons into superoxide, and drops ATP output. SS-31 prevents that peroxidation; it stabilizes cristae architecture and restores electron flow at the source rather than scavenging free radicals after they form. Preclinical models show reversed age-related cardiac dysfunction [2], improved renal filtration, and neuroprotection from ischemia-reperfusion injury.
The longevity community has adopted SS-31 at doses between 2 and 10 mg daily, well below the 40 mg FDA-approved dose. No dose-finding trial exists in healthy adults, so these community doses are pragmatic cost and tolerability decisions rather than clinically validated thresholds. Reports from roughly 50 to 100 threads across r/Peptides, r/longevity, and r/Nootropics describe subtle energy gains, better exercise recovery, and reduced fatigue. Injection site reactions affect nearly all users.
How SS-31 (Elamipretide) Works
SS-31 is a cell-permeable tetrapeptide with an alternating aromatic-cationic motif. That structure lets it cross lipid bilayers without needing mitochondrial membrane potential as a driving force. Once inside the cell, it accumulates more than 1,000-fold within mitochondria.
The target is cardiolipin. This anionic phospholipid sits exclusively on the inner mitochondrial membrane, where it anchors cytochrome c and holds the electron transport chain complexes in their functional supercomplex arrangements. When cardiolipin oxidizes (a consistent hallmark of aging and mitochondrial disease), cristae flatten out. Electron transfer between complexes III and IV slows. Electrons leak sideways to form superoxide. ATP production falls.
SS-31 binds directly to cardiolipin and blocks peroxidation. Cristae architecture stays intact. Electron flow through the ETC normalizes. Reactive oxygen species drop at the point of generation, not downstream. The result: improved ATP synthesis, preserved mitochondrial membrane potential, and blocked cytochrome c release, which prevents the intrinsic apoptosis cascade.
In aged mice, 8 weeks of SS-31 reversed cardiac diastolic dysfunction and improved contractile reserve [2]. The TAZPOWER open-label extension [1] tracked 12 Barth syndrome patients for 168 weeks and confirmed sustained functional improvements. MMPOWER-3 (n=218)[3] tested SS-31 in primary mitochondrial myopathy; the overall primary endpoint was not met, though a nDNA-variant subgroup showed gains on the 6-minute walk test.
SS-31 (Elamipretide) Benefits
- SS-31 benefits center on mitochondrial protection and cellular energy restoration.
- Cardiolipin stabilization at the source. SS-31 prevents the lipid peroxidation that collapses cristae and disrupts electron transport, targeting aging where it starts.
- 42% knee extensor strength increase at 168 weeks in the TAZPOWER open-label extension (n=12 Barth syndrome patients)[1].
- Heart protection in preclinical models. Eight weeks of SS-31 reversed diastolic dysfunction in aged mice, restoring cardiac function to near-young levels [2].
- Improved exercise recovery reported consistently across community users at 4 to 10 mg daily, with reduced post-workout fatigue and better tolerance during training.
- ROS reduction at the electron transport chain rather than downstream scavenging; a mechanistic advantage over conventional antioxidants like vitamin C or CoQ10.
- Renal protection in preclinical ischemia-reperfusion models, preserving glomerular filtration through mitochondrial stabilization in kidney tubular cells.
SS-31 (Elamipretide): Science vs Community Consensus
FDA accelerated approval granted September 19, 2025 (NDA 215244, FORZINITY) for Barth syndrome: based on open-label extension knee extensor strength improvement, NOT the randomized phase endpoints.
Read the evidence (key study, limitations)
The 12-week RCT crossover primary endpoints (6-minute walk test, total fatigue score) were NOT met. MMPOWER-3 Phase 3 (primary mitochondrial myopathy) also failed primary endpoint in the overall population; nDNA-variant subgroup showed 6MWT improvement. No FDA approval for HFpEF or any other indication as of October 2026 (Drugs@FDA). Mechanistic evidence is very strong (cardiolipin stabilization, ROS reduction, ETC restoration). No dose-finding trial in healthy adults exists.
PMID 38602181: TAZPOWER 168-week open-label extension (Barth syndrome, n=12); PMID 37268435: MMPOWER-3 Phase 3 (PMM, n=218)
Accelerated approval contingent on confirmatory trial verifying clinical benefit. Primary RCT phase of TAZPOWER missed both endpoints. MMPOWER-3 failed overall primary endpoint. All trials conducted in disease populations (Barth syndrome, PMM, HFpEF): no RCT in healthy aging adults. Community doses (1–20 mg) are 2–40× below the studied 40 mg clinical dose with no head-to-head data. Long-term safety beyond 168 weeks unstudied. Phase 3 trial sizes are small (n=12–218) due to orphan-disease context.
Niche but growing.
Read the reports (what users report 5, common issues 5)
Primarily used by longevity/biohacking community for energy, fatigue, and exercise recovery. Reports are cautiously positive. Major barriers: dose uncertainty (0.5 mg vs 40 mg), high cost, and injection site reactions in virtually all users. Community consensus has converged around 4–10 mg/day as the "standard" research dose, with some beginning at 500 mcg–2 mg.
- Reduced fatigue and improved baseline energy levels
- Better exercise recovery and reduced post-workout soreness
- Subtle improvements in exercise tolerance and endurance
- Anecdotal cognitive clarity and reduced brain fog
- Perceived anti-aging / longevity "insurance" use case
- Injection site erythema, pain, and induration (100%, 75%, 67% in TAZPOWER: very high incidence)
- Eosinophilia in majority of users during first 90 days (usually asymptomatic but can be alarming on CBC)
- Cost: research-grade $50–$80 per 10 mg vial; 10 mg/day = $150–$240/month minimum
- Dose ambiguity: community uses 4–10× lower than the only studied clinical dose (40 mg)
- No perceived effect is common early; mitochondrial improvements may not be subjectively noticeable
Science and community agree on the mitochondrial-cardiolipin mechanism. The FDA-approved 40 mg dose reflects a serious disease population; community extrapolates a lower minimum effective dose for healthy aging adults without supporting trial data. Neither confirmed nor refuted: data gap, not contradiction.
SS-31 (Elamipretide) Dosage Guide
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 4 mg | DailyTrack |
| Moderate | 10 mg | DailyTrack |
| Aggressive | 40 mgThis is the FORZINITY label dose for Barth syndrome in patients 30 kg and up (label section 2.1). FORZINITY is a ready-to-use 80 mg/mL solution, so 40 mg is 0.5 mL drawn straight from the vial with nothing added (sections 3 and 11). SS-31 vial and BAC water math applies to research-grade powder only. | DailyTrack |
Reconstitution math first, for research-grade powder vials. A 10 mg vial with 1 mL bacteriostatic water gives you 10 mg/mL. At that concentration, 4 mg equals 40 units on a U-100 insulin syringe (0.4 mL). A 10 mg dose takes the full syringe (100 units, 1.0 mL). For the 40 mg vial, add 4 mL BAC water for the same 10 mg/mL concentration; 10 mg is still 100 units, but you get four doses per vial instead of one.
FORZINITY, the FDA-approved product, skips all of this. It is a ready-to-use 80 mg/mL solution in a 280 mg/3.5 mL vial (label section 3). Its 40 mg dose is 0.5 mL, drawn with the syringe your healthcare provider prescribes (sections 2.1 and 11, Instructions for Use).
Morning dosing is the community standard. There is no meal timing requirement.
You'll want to pre-treat injection sites. Cetirizine 10 mg taken 30 minutes before your shot makes a real difference for the first few weeks. Rotate between abdomen and upper thigh, and inject slowly. The site reactions are the number one reason people quit early.
Get a CBC at baseline and again at week 8. The eosinophilia is expected, but you want a record showing it was absent before you started.
No published stability data exist for reconstituted research-grade SS-31. Community reports keep sealed powder at -20°C and the mixed vial at 2-8°C for up to 28 days. Keep unopened FORZINITY vials at 2-8°C and never freeze them. After the first dose, an opened vial can stay at 2-8°C or at 20-25°C; discard it 8 days after first opening (label section 16.2).
SS-31 does not exhibit receptor desensitization, hormonal axis suppression, or documented antibody formation. Clinical trials used continuous daily dosing for up to 168 weeks (TAZPOWER open-label extension) without cycling. Community cycling (typically 12 weeks on, 4 weeks off) is cost-driven, not biologically required.
- No established biological signs of tolerance or receptor downregulation with SS-31
- Cost fatigue (≥$150–$300/month at community doses) is the primary practical cycling driver
- A planned break after 12–16 weeks can serve as a useful baseline reassessment window
Or use the universal Peptide Calculator for any peptide.
SS-31 (Elamipretide) Protocols by Goal
Expected: Modest improvement in energy and exercise recovery by weeks 4–6. Effects are subtle at this dose range: no clinical RCT data supports efficacy at 4 mg in healthy adults.
Monitor: Optional CBC at baseline and week 8 to monitor for eosinophilia. No other formal monitoring required for healthy adults at this dose.
How to Inject SS-31 (Elamipretide)
- 1Step 1
Wash hands thoroughly and clean the vial stopper with an alcohol swab.
- 2Step 2
Research-grade powder only: draw bacteriostatic water into a syringe. Use 1 mL for a 10 mg vial (gives 10 mg/mL) or 4 mL for a 40 mg vial (same 10 mg/mL concentration). Inject water down the side of the vial, not directly onto the powder.
- 3Swirl gently until dissolved
SS-31 dissolves quickly. Do not shake.
- 4Step 4
Draw your dose of mixed research-grade powder with a U-100 insulin syringe (29 or 30 gauge, 0.5 inch needle). At 10 mg/mL: 20 units equals 2 mg, 40 units equals 4 mg, 100 units equals 10 mg. FORZINITY is a ready-to-use 80 mg/mL solution with nothing to mix or swirl. Draw the prescribed dose in mL, using only the syringe your healthcare provider prescribes. 40 mg is 0.5 mL (label sections 2.1 and 11, Instructions for Use).
- 5Step 5
Clean the injection site (abdomen or upper thigh) with an alcohol swab. Let dry.
- 6Pinch skin and insert needle at a 45 to 90 degree angle
Inject slowly over 30 to 60 seconds. Slow injection reduces site reactions.
- 7Rotate injection sites each day
Alternate between left abdomen, right abdomen, left thigh, and right thigh.
- 8Step 8
Research-grade powder: store the mixed vial at 2-8°C (a standard refrigerator) and use it within 28 days. That figure comes from community reports; no published stability data exist for reconstituted research-grade SS-31. FORZINITY: keep an opened vial at 2-8°C or 20-25°C and discard it 8 days after first opening (label section 16.2).
- 9Dose timing: morning, same time each day
No food restriction required.
SS-31 (Elamipretide) Stacking Protocols
Works With
Complementary mitochondrial mechanisms: SS-31 addresses cardiolipin/structural ETC function; NAD+ restores sirtuin signaling and cofactor availability. Additive without redundancy.
SS-31 morning SubQ + NAD+ SubQ 100–250 mg 2–3×/week
Dual mitochondrial optimization: SS-31 targets inner membrane cardiolipin; MOTS-c activates AMPK via nuclear retrograde signaling. Address structural and metabolic mitochondrial function together.
SS-31 daily SubQ + MOTS-c 5–10 mg 3×/week SubQ
Tissue repair pairing: BPC-157 promotes angiogenesis and cellular healing; SS-31 protects mitochondria in stressed/injured tissue. Used together in recovery and injury contexts.
SS-31 + BPC-157 250–500 mcg daily, both SubQ, separate injections
Broad anti-aging pairing: GHK-Cu supports collagen synthesis and tissue remodeling; SS-31 targets cellular energy production. Non-overlapping mechanisms.
Avoid
Both target the inner mitochondrial membrane. Overlapping mechanism may produce unpredictable additive effects on membrane dynamics; no formal interaction studies.
Cyclosporine inhibits mPTP (mitochondrial permeability transition pore): overlapping mechanism with SS-31 cardiolipin stabilization. Combined effects unpredictable; no interaction data.
SS-31 mitochondrial protection may mask early cardiotoxicity signals from anthracyclines. Concurrent use requires close cardiac monitoring.
Do not combineEstimated Cost
Pricing updated 2026-04-09
SS-31 (Elamipretide) Side Effects
Injection site reactions are the defining tolerability challenge with SS-31. In the TAZPOWER trial [4], 100% of participants developed injection site erythema. 75% reported pain. 67% experienced induration. These numbers are not typical for subcutaneous peptides. Community reports confirm the clinical data: redness, swelling, and a firm lump at the injection site are expected, not exceptional.
Site rotation between abdomen and upper thigh helps. Reactions typically moderate after 2 to 4 weeks of consistent use. Topical 1% hydrocortisone cream or oral cetirizine 10 mg before injection can reduce severity. Injecting slowly over 30 to 60 seconds also helps based on community experience. If induration expands, feels warm, or shows discharge, stop and evaluate for sterile abscess.
Eosinophilia is the second major concern. Raised eosinophil counts are common after 30 or more days of SS-31, with levels peaking around day 90. This shows up on a CBC and can be alarming if unexpected. In elamipretide trials, the rise was not linked to symptoms or other lab changes. Counts returned to baseline after 6 to 12 months of continued use, or after stopping (section 6.1). Do not discontinue solely for isolated eosinophilia without symptoms. If wheeze, GI distress, rash, or other organ-specific symptoms appear alongside raised eosinophils, stop SS-31 and consult a physician immediately.
The FORZINITY label carries two warnings (section 5). The first is allergic reactions, including serious ones that needed emergency care, with rash, papular lesions, eczematous dermatitis or cough (section 5.2). They can start anywhere from minutes to months after the first dose.
At any sign of an immediate allergic reaction, stop and get medical help right away (section 17). After a serious reaction, the label says not to restart it. Mild to moderate skin reactions can be treated with a topical corticosteroid and an oral antihistamine, though persistent or severe ones may mean stopping.
The second warning is benzyl alcohol. FORZINITY contains 20 mg/mL as a preservative, and the label says "Do not use in neonates" (section 5.1). Serious and fatal reactions have been reported in low-birth-weight and preterm newborns given benzyl alcohol-containing drugs intravenously (sections 5.1 and 8.4).
Pregnancy and breastfeeding are not contraindications on the FORZINITY label (section 4). Barth syndrome is unlikely to affect females, so there are no data in pregnant women and the risk of birth defects or miscarriage is unknown. Rat and rabbit studies found no harm to development at any dose tested (section 8.1).
No data show whether FORZINITY reaches breast milk or affects a breastfed infant. The label weighs breastfeeding's benefits against the mother's need for the drug and any possible harm to the infant (section 8.2). All of this describes FORZINITY; research-grade SS-31 powder is a different product with no safety testing of its own. The MMPOWER-3 trial excluded pregnant or breastfeeding women and required highly effective birth control for women who could become pregnant (NCT03323749).
Two cautions here come from research, not the FORZINITY label. People with active cancer should avoid SS-31, since no carcinogenicity studies exist (section 13.1) and MMPOWER-3 excluded active cancer (NCT03323749). That trial also excluded most active cardiac conduction abnormalities, so safety in that group is unknown.
Renal impairment matters. SS-31 is renally excreted. The FDA label calls for dose reduction to 20 mg daily for severe renal impairment (eGFR under 30, not on dialysis). Baseline renal function should be checked before starting.
Long-term safety beyond 168 weeks has not been characterized. Community users running sub-clinical doses (2 to 10 mg) have less safety data coverage than trial participants at 40 mg. Lower doses likely carry lower risk, but this assumption lacks trial validation.
Common Issues & Solutions
Injection site reactions (erythema, pain, induration): Expected in nearly all users. Apply topical 1% hydrocortisone cream or take cetirizine 10 mg before injection. Reactions typically improve after 2–4 weeks with consistent site rotation (abdomen and upper thigh alternating).
Eosinophilia on CBC: Common after 30+ days; peaks ~day 90. In elamipretide trials, counts returned to baseline after 6 to 12 months of use or after stopping (label section 6.1). Do not discontinue unless accompanied by organ-specific symptoms (wheeze, GI distress, rash). Counts may still be raised at week 16, so repeat the CBC later to track the trend.
No perceived effect at community doses (1–10 mg): Common. Mitochondrial improvements may manifest as subtle energy and recovery changes rather than dramatic subjective effects. Clinical benefit at sub-40 mg doses is not RCT-proven in healthy adults: track objective metrics (exercise performance, HRV, fatigue scores).
High cost / supply interruption: research-grade supply can end partway through a cycle.
Dose confusion (0.5 mg vs 10 mg vs 40 mg): Community uses 0.5–20 mg; the only clinical trial dose was 40 mg/day in disease populations. No validated minimum effective dose for healthy adults. Lower community doses are pragmatic cost/tolerability decisions: not clinically validated efficacy thresholds.
Ask AI about this page
Ask AI for a second opinion on SS-31 (Elamipretide) dosing and side effects
Contraindications
- Serious hypersensitivity to elamipretide or any FORZINITY excipient: the one contraindication on the FORZINITY label (section 4). Serious allergic reactions needing emergency care have occurred, from minutes to months after starting, and the label says not to restart after one (section 5.2)
- Pregnancy and breastfeeding: not a contraindication on the FORZINITY label. The label has no data in pregnant women, so the risk of birth defects or miscarriage is unknown. In rat and rabbit studies, no harm to development occurred at any dose tested (section 8.1). No data show whether it reaches breast milk or affects a breastfed infant. The label weighs breastfeeding's benefits against the mother's need for FORZINITY and any possible harm to the infant (section 8.2). These findings come from FORZINITY's label; research-grade powder is a different product with no safety testing of its own. The MMPOWER-3 trial excluded pregnant or breastfeeding women and required highly effective birth control for women who could become pregnant (NCT03323749)
- Severe renal impairment: a dose change, not a contraindication on the FORZINITY label. FORZINITY's dose is halved to 20 mg once daily for adults with eGFR under 30 mL/min who are not on dialysis (sections 2.2 and 8.6). Mild or moderate impairment needs no change. There is no labelled dose for adults on dialysis or for children with renal impairment. Elamipretide is excreted in the urine; exposure rose 125% in severe impairment (section 12.3)
- Children under 30 kg: safety and effectiveness have not been established (section 8.4). The label dose is for patients 30 kg and up (section 2.1)
- Newborns: the label says "Do not use in neonates" (section 5.1). FORZINITY contains 20 mg/mL benzyl alcohol as a preservative. Serious and fatal reactions, including gasping syndrome, have been reported in low-birth-weight and preterm newborns given benzyl alcohol-containing drugs intravenously (sections 5.1 and 8.4)
- Active malignancy or history of cancer: a research caution, not on the FORZINITY label. No carcinogenicity studies have been done (label section 13.1), and MMPOWER-3 excluded active cancer or cancer within the past 2 years (NCT03323749)
- Severe cardiac conduction abnormalities: a research caution, not on the FORZINITY label. MMPOWER-3 excluded most active conduction abnormalities (NCT03323749), so safety in this group is not established
Drug Interactions
- Anthracycline chemotherapeutics (doxorubicin, daunorubicin): SS-31 may mask early signs of cardiotoxicity by protecting mitochondria; monitor cardiac function closely if co-administered
- Other mitochondrial-targeted compounds (MitoQ, CoQ10, idebenone): no formal interaction studies; theoretical additive effects on mitochondrial membrane dynamics
- Immunosuppressants (cyclosporine A): cyclosporine inhibits mitochondrial permeability transition pore opening, which overlaps with SS-31 mechanism; potential for unpredictable combined effects
- Insulin and oral hypoglycemics: while SS-31 does not directly affect glucose metabolism, improved mitochondrial function may alter insulin sensitivity; monitor blood glucose
- Anticoagulants: no known pharmacokinetic interaction, but as with all subcutaneous injectables, monitor for injection site bruising
Product Quality
SS-31 (elamipretide) is now an FDA-approved pharmaceutical (FORZINITY, NDA 215244, September 2025). Pharmaceutical-grade FORZINITY is an orphan drug with prohibitive cost outside clinical use.
- A useful CoA shows HPLC purity ≥98% and mass spec confirmation
- Endotoxin risk stays unknown without third-party endotoxin testing (LAL assay)
- Research-grade powder is mixed with bacteriostatic water (BAC water); FORZINITY is a ready-to-use 80 mg/mL solution and is never mixed (label sections 3 and 11)
- Community reports store sealed research-grade powder at -20°C and the mixed vial at 2-8°C for up to 28 days. No published stability data exist for reconstituted research-grade SS-31
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| CBC with differential | Baseline, then at week 8 and week 16 | Eosinophils <500 cells/μL (normal); mild elevation 500–1,500/μL acceptable if asymptomatic; >1,500/μL investigate for organ involvement |
| Renal function panel (BMP or CMP) | Baseline; repeat at week 12 if any renal compromise or for long-term continuous use | eGFR ≥30: no dose change for mild or moderate impairment; eGFR <30 and not on dialysis: half dose (label: 20 mg/day); on dialysis: no labelled dose |
| Injection site visual assessment | Each injection cycle: inspect prior site before next injection | Not listed |
Eosinophilia is common after 30 or more days of SS-31 use and peaks around day 90. In elamipretide trials, counts returned to baseline after 6 to 12 months of use or after stopping (label section 6.1). Monitor the trend and rule out eosinophilic organ involvement.
Elamipretide is excreted in the urine (section 12.3). The FDA label halves its 40 mg dose to 20 mg/day below eGFR 30 mL/min without dialysis. It gives no dose for dialysis (sections 2.2 and 8.6)
Near-universal injection site reactions; expanding induration, warmth, or purulent discharge may indicate sterile abscess or infection requiring intervention
SS-31 (Elamipretide) Before and After
SS-31 begins accumulating in mitochondrial membranes. Cardiolipin stabilization starts at the molecular level. Most users notice no outward changes yet. Injection site reactions (redness, mild soreness) are the most common early experience.
Mitochondrial ETC efficiency begins to improve. Some individuals report subtle increases in baseline energy and reduced fatigue during daily activities. ROS production at the inner membrane decreases measurably in preclinical models at this timepoint.
Clinical trial data shows measurable improvements in 6-minute walk test distance and reduced fatigue scores in Barth syndrome patients during this window. Users may notice improved exercise tolerance, better recovery from physical exertion, and more consistent energy throughout the day.
Continued improvement in mitochondrial function. Cardiac parameters such as stroke volume and cardiac output showed improvement in open-label extension studies. Skeletal muscle strength and endurance gains become more noticeable.
Long-term open-label data (up to 168 weeks in TAZPOWER) showed sustained improvements in cardiac and functional outcomes. Protocol duration beyond 12 weeks should be guided by a physician. Long-term safety beyond clinical trial settings is not fully established.
What to Expect
Weeks 1 to 2, Titration and Tolerance Assessment: Cardiolipin binding begins at the molecular level during this window. Electron transport chain stabilization starts, but nothing measurable shows up clinically. Most users notice zero benefits. Injection site reactions dominate the experience, with near-universal redness, pain in about 75% of users, and induration in roughly 67%. This is normal, not a reason to quit.
Weeks 3 to 6, Early Mitochondrial Adaptation: Preclinical models show measurable ROS reduction and improved ATP synthesis by this point. Some users pick up on subtle energy improvements and better exercise tolerance. Post-workout fatigue may ease modestly. Injection site reactions start moderating if you are rotating sites. Eosinophilia begins appearing on CBC after 30 days of use; it is typically asymptomatic.
Weeks 6 to 12, Functional Improvement Window: The TAZPOWER open-label extension recorded 16% improvement in 6-minute walk test distance and 19% improvement in fatigue scores by week 12. Knee extensor strength gained 30% from study baseline. Community users report more consistent daily energy, improved exercise performance, and better recovery. Some describe cognitive clarity. Eosinophils peak around day 90 and then begin normalizing.
Weeks 12 to 24, Sustained Benefit and Stabilization: By week 36 of TAZPOWER, improvements reached 25% on the 6-minute walk test, 26% for fatigue scores, and 42% for knee extensor strength (all open-label data). Community users who continue past 12 weeks report maintained benefits. Cost fatigue leads many to take a planned break or drop to lower maintenance dosing. Eosinophil counts may still be raised. In elamipretide trials, they returned to baseline after 6 to 12 months of use or after stopping.
Weeks 24 to 168 and beyond, Long-Term Maintenance: The TAZPOWER 168-week open-label extension showed sustained cardiac and functional improvements with no new safety signals in Barth syndrome patients. Long-term community data is sparse. Most people cycle for cost reasons rather than biological necessity. Benefits appear maintained in those who continue. Long-term safety in healthy aging adults has not been characterized beyond the clinical trial population.
Detailed Timeline: Science vs Community
Cardiolipin binding begins; ETC structural stabilization starts at molecular level. No measurable functional changes detectable clinically this early.
Most users report no noticeable benefits. Injection site reactions are the dominant early experience.
Preclinical models show measurable ROS reduction and improved ATP synthesis at this timepoint. Eosinophilia begins to appear on CBC (>30 days of use).
Subtle energy improvements reported by some users. Better exercise tolerance and modest reduction in post-workout fatigue. Injection site reactions begin to moderate with site rotation.
TAZPOWER open-label extension: 16% improvement in 6MWT and 19% improvement in fatigue scores by week 12; knee extensor strength +30% from study baseline.
More consistent daily energy, improved exercise performance, better recovery. Some report cognitive clarity. Peak eosinophilia around day 90.
TAZPOWER week 36: 25% improvement in 6MWT, 26% fatigue improvement, 42% knee extensor strength increase from study baseline (open-label data).
Maintained benefits. Cost fatigue leads many to take a planned break or transition to lower maintenance dosing.
TAZPOWER 168-week open-label extension showed sustained cardiac and functional outcome improvements with no new safety signals.
Long-term community data is sparse. Most cycle for cost reasons rather than safety. Benefits appear maintained in long-term users.
Pharmacokinetics
Source: Plasma elimination half-life of ~4 hours after subcutaneous administration in human clinical trials (PMID 29500292)
Pharmacokinetics: Active Dose Over Time
t½ = ~4 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is SS-31 (Elamipretide) Legal?
SS-31 (elamipretide) received FDA accelerated approval on September 19, 2025 under the brand name FORZINITY (NDA 215244) for treatment of Barth syndrome in adults and pediatric patients weighing at least 30 kg. Continued approval is contingent on a confirmatory clinical trial verifying clinical benefit.
FORZINITY is manufactured by Stealth BioTherapeutics. As of October 2026, Drugs@FDA lists no approval for any other indication, including heart failure.
SS-31 has historically been sold as a research peptide under various names (SS-31, MTP-131, Bendavia).
SS-31 is sold for research purposes only through non-pharmaceutical channels. It is not WADA-listed as of early 2026, though athletes should verify current prohibited substance lists before use. This content is for educational and informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before using any peptide.
Who Should Consider SS-31 (Elamipretide)
- Adults with age-related mitochondrial dysfunction seeking to restore cellular energy
- Patients with Barth syndrome (FDA accelerated approval granted for this indication)
- Individuals with primary mitochondrial myopathy experiencing exercise intolerance
- Older adults with declining cardiac function related to mitochondrial impairment
- Patients with heart failure with preserved ejection fraction (HFpEF) under clinical investigation
- Adults interested in longevity interventions targeting the root cause of cellular aging
Related Peptides
What Changed for SS-31 (Elamipretide)
- Safety
Corrected Oct 16, 2026: SS-31 pregnancy risk is unknown, not contraindicated; allergy and newborn benzyl alcohol warnings added, per the FORZINITY label.
Before: No reproductive safety data exists; SS-31 contraindicated in pregnancy and breastfeeding; no allergic reaction warning; benzyl alcohol called no concern for adults; eosinophilia said to clear by week 16 to 20 After: Not a label contraindication: no human pregnancy data, no harm in rat and rabbit studies (8.1), breastfeeding weighed against need (8.2); the section 5.1 and 5.2 warnings stated; eosinophil counts back to baseline after 6 to 12 months of use or after stopping (6.1)
What this does not mean: There are still no human pregnancy data, so the risk is unknown. The page had said no reproductive data existed; rat and rabbit studies found no harm to development (section 8.1).
Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy
- Dosing
Corrected Oct 16, 2026: FORZINITY is a ready 80 mg/mL solution, so its 40 mg dose is 0.5 mL drawn with nothing mixed in, per the FORZINITY label.
Before: Aggressive 40 mg daily, the FORZINITY label dose, with no note on its form beside the vial and BAC water math After: Aggressive 40 mg daily, noted as the FORZINITY label dose: a ready 80 mg/mL solution, 0.5 mL drawn from the vial with nothing added
What this does not mean: FORZINITY's label did not change. The 4, 10 and 40 mg tiers are unchanged, and the calculator's vial and BAC water math still applies to research-grade powder only.
Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 16, 2026: serious hypersensitivity is the one label contraindication; pregnancy (risk unknown) and severe renal impairment are not, per FORZINITY.
Before: Pregnancy or breastfeeding listed as contraindicated for lack of reproductive safety data, severe renal impairment listed as a contraindication, and known hypersensitivity After: Serious hypersensitivity, the one label contraindication (sections 4 and 5.2); pregnancy and breastfeeding per sections 8.1 and 8.2; severe renal impairment as the half dose of sections 2.2 and 8.6
What this does not mean: Pregnancy risk is still unknown, since there are no human data; rat and rabbit studies found no harm. Severe renal impairment halves the label dose to 20 mg. Research-grade powder has no safety testing of its own.
Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy
- Dosing
Corrected Oct 9, 2026: the 4 mg and 10 mg SS-31 tiers are community doses; the FORZINITY label dose is 40 mg once daily, per the FDA label.
Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations
References
- [1]Long-term efficacy and safety of elamipretide in Barth syndrome: 168-week open-label extension results of TAZPOWER (Genet Med 2024) (opens in a new tab)(n=12)PubMed (opens in a new tab)PubMed
- [2]Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice (eLife 2020) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]MMPOWER-3: Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial (Karaa et al., Neurology 2023) (opens in a new tab)(n=218)PubMed (opens in a new tab)PubMed
- [4]A phase 2/3 randomized clinical trial to evaluate elamipretide in Barth syndrome: TAZPOWER (Genet Med 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]FDA NDA 215244
Additional References
- Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential (Int J Mol Sci 2025) (opens in a new tab)PubMed 39940712Review
- Mitochondrial protein interaction mapping of SS-31 (PNAS 2020) (opens in a new tab)PubMed 32554501PubMed
- Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy (Neurology 2018) (opens in a new tab)PubMed 29500292PubMed
- FORZINITY (elamipretide) injection FDA Prescribing Information (opens in a new tab)FDA Label
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is SS-31 (Elamipretide)?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 50–100+. Community mentions on Reddit: ~50–100+ threads estimated (r/peptides, r/longevity, r/Nootr. Open r/peptides (opens in a new tab).
559 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.